Conditions
Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Endometrial Neoplasms, Oesophageal Neoplasms, Pancreatic Ductal Adenocarcinoma
Clinical Trials
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumours including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC), and oesophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
NATIONAL TRIAL REFERENCE NUMBER
NCT04976634
EudraCT
2020-005007-40
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Colorectal Neoplasms, Endometrial Neoplasms, Oesophageal Neoplasms, Pancreatic Ductal Adenocarcinoma
Age Range
18+
Sex
All
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
If you are considering joining a clinical trial, first learn as much as you can about:
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about